Kevin joined EQT Life Sciences as an Associate in July 2022.
Prior to EQT Life Sciences, he worked in R&D at BioMarin Pharmaceutical with a focus on clinical pharmacology, PK/PD and pharmacometrics. While at BioMarin, Kevin contributed to the approval of several therapies including Roctavian (AAV5 gene therapy for hemophilia A), and Palynziq (biologic for phenylketonuria). Prior to BioMarin, he worked in Amgen's Clinical Pharmacology Modelling and Simulation group.
Kevin has a MBA from INSEAD, and a B.S. in Pharmacology from the University of California, Santa Barbara.